SERAZAPINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H23N3O2.ClH
Molecular Weight	397.898
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC(=O)C1=C2C3CN(C)CCN3C4=C(CN2C5=C1C=CC=C5)C=CC=C4

InChI

InChIKey=YEITZTKANLXOTH-UHFFFAOYSA-N

InChI=1S/C22H23N3O2.ClH/c1-23-11-12-24-17-9-5-3-7-15(17)13-25-18-10-6-4-8-16(18)20(22(26)27-2)21(25)19(24)14-23;/h3-10,19H,11-14H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	C22H23N3O2
Molecular Weight	361.4369
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8104044 | https://books.google.ca/books?id=xUlaDwAAQBAJ&pg=PT1178&lpg=PT1178&dq=SERAZAPINE+drug&source=bl&ots=CnAWmMiDbV&sig=ACfU3U33B6BN8vFXW-6o9p_Cau5-MUiRKQ&hl=en&sa=X&ved=2ahUKEwjfjuC2i4njAhVJaM0KHQhkCbQQ6AEwCnoECAkQAQ#v=onepage&q=SERAZAPINE%20drug&f=false retrieved from Drugs: Synonyms and Properties: Synonyms and Properties edited by George W.A Milne

Serazapine (CGS15040) is an anxiolytic agent. It is structurally novel 5-HT2 receptor antagonist. Preliminary preclinical findings indicated an anticonflict effect in a behavioral suppression test, and two preliminary investigations in volunteers also suggested anxiolytic potential. In the first of these studies serazapine resembled diazepam, a reference anxiolytic drug, electroencephalographically. Additionally, in a test of psychogenic stress in volunteers it reduced cardiac output.

Originator

Approval Year

PubMed

Title	Date	PubMed
Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder.	1993-07-01	8104044
Determination of CGS 15040A in human plasma by liquid chromatography.	1991	1680469

Patents

Sample Use Guides

In Vivo Use Guide

A double-blind, randomized, placebo-controlled four-compartment parallel group, multicenter trial in outpatients with Generalized Anxiety Disorder (GAD): a 14-to 30-day drug-free interval preceded study entry. For all qualified patients, a 1-week, single-blind placebo washout period was followed by a 5-week, double-blind treatment phase involving a once daily oral dose of either 10 mg, 20 mg, or 40 mg of Serazapine (CGS15040), or placebo. The 40-mg group tended to perform better (larger decreases from baseline in the total Ham-A score) than the other groups.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:51:06 GMT 2025` Edited by `admin` on `Mon Mar 31 17:51:06 GMT 2025`
Record UNII	962IFR72N1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CGS 15040A

Preferred Name

English

SERAZAPINE HYDROCHLORIDE

Official Name

English

2H,10H-INDOLO(2,1-C)PYRAZINO(1,2-A)(1,4)BENZODIAZEPINE-16-CARBOXYLIC ACID, 1,3,4,16B-TETRAHYDRO-2-METHYL-, METHYL ESTER, MONOHYDROCHLORIDE

Common Name

English

CGS-15040A

Code

English

2H,10H-INDOLO(2,1-C)PYRAZINO(1,2-A)(1,4)BENZODIAZEPINE-16-CARBOXYLIC ACID, 1,3,4,16B-TETRAHYDRO-2-METHYL-, METHYL ESTER, HYDROCHLORIDE (1:1)

Systematic Name

English

SERAZAPINE HYDROCHLORIDE [USAN]

Common Name

English

Serazapine hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28197